Study of trastuzumab in combination with pertuzumab in patients already treated with a lung cancer harboring a Her2 mutation and receiving docetaxel

Phase 1

• Conditions: on small cell lung cancer with a Her2 mutation; MedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 23.0Level: PTClassification code 10075653Term: HER2 gene amplificationSystem Organ Class: 10010331 - Congenital, familial and genetic disorders; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2018-003506-11-FR
• Lead Sponsor: IFCT

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-03-07
• Last Update Posted: 12 March 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

1.Patient having signed an informed consent form
2.Histologically or cytologically confirmed NSCLC (per 2015 8th edition TNM classification)
3.Not suitable for radiation, inoperable stage III or stage IV
4.HER2 exon 20 mutation or insertion among which: in-frame insertions in exon 20 between codons 775 and 881 including the 12bp insertion with a duplication / insertion of 4 amino acids (YVMA) at codon 775, the 3bp insertion with a complex insertion-substitution G776>VC and point mutations L755S and G776C. Other mutation/insertion should be discussed with IFCT. Analysis must be performed in INCa-labelled laboratories or platforms according to a validated procedure.
5.Prior treatment with at least one regimen of platinum-based chemotherapy with documented disease progression.
Note: taxanes are allowed provided that no grade >2 associated adverse event occurred (except hematological toxicity).
6.Presence of at least one lesion that can be measured by CT scan (RECIST v1.1)
7.Age = 18 years
8.Adequate organ function, as evidenced by the following laboratory results:
ANC > 1500 cells/mm3
Platelet count > 100,000 cells/mm3
Hemoglobin > 9.0 g/dL
Patients are allowed to receive transfused RBC to achieve this level.
Total bilirubin = 1.5 × ULN, except in patients with previously documented Gilbert’s syndrome, in which case the direct bilirubin should be less than or equal to the ULN
SGOT and SGPT = 2.5 × ULN Alkaline phosphatase = 2.5 × ULN, Alkaline phosphatase < 5×ULN and SGOT and SGPT < 5×ULN for patients with hepatic and/or bone metastases
Clearance creatinine = 30 mL/min
INR and aPTT ? 1.5 ? ULN
This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.
9.WHO performance index of 0, 1 or 2
10.LVEF = 50%
11.Patient who is capable, according to the investigator, of complying with the study's requirements and restrictions
12.Estimated life expectancy > 3 months
13.A female is eligible to enter and participate in this study if she is of:
Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has undergone:
•Hysterectomy.
•Bilateral oophorectomy (ovariectomy).
•Bilateral tubal ligation.
•Or who is post-menopausal:
•Patients not using hormone replacement therapy (HRT) must have experienced total cessation of menses for =1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone value >40 mIU/mL and an estradiol value <40 pg/mL (<140 pmol/L).
•Patients must discontinue HRT prior to study enrolment due to the potential for inhibition of cytochrome enzymes that metabolize estrogens and progestins. For most forms of HRT, at least 2 4 weeks must elapse between the cessation of HRT and determination of menopausal status; length of this interval depends on the type and dosage of HRT. If a female subject is determined not to be post-menopausal, they must use adequate contraception, as defined immediately below.
Childbearing potential, including any female who has had a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception during the study and for at least 7 months after the last dose of investigational product. Contraceptive methods acceptable to IFCT, when used consistently and in accordance with

Exclusion Criteria

1.History of cancer except cancer dating from over two years ago and considered to be cured, appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma and stage I uterine cancer.
2.Any approved anti-cancer therapy = 21 days before enrollment. Note: TKIs approved for the treatment of NSCLC must be discontinued = 7 days prior to the first study treatment on Cycle 1, Day 1. (The baseline scan must be completed after discontinuation of TKIs).
3.Patients with concomitant EGFR, ALK, ROS1, MET, BRAF and KRAS mutation. Other molecular co-alterations should be discussed with IFCT before patient’s enrollment.
4.Previous treatment with an anti-HER2 agent.
5.Any other investigational therapy = 28 days before inclusion
6.Previous irradiation <14 days before enrollment.
7.Brain metastases that are symptomatic, or require any radiation, surgery, or corticosteroid therapy to control symptoms from brain metastases within 4 weeks before enrollment. Asymptomatic brain metastases with a fixed dose of steroids for at least 2 weeks are eligible.
8.Carcinomatous meningitis
9.History of intolerance (including Grade 3 or 4 infusion reaction) or hypersensitivity to trastuzumab, pertuzumab or docetaxel or murine proteins or one of the excipients
10.Pregnancy and breast-feeding
11.Any evidence of severe or uncontrolled systemic disease. (E.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) or other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study.
12.Evidence of active pneumonitis during screening
13.Current unstable ventricular arrhythmia requiring treatment, history of symptomatic congestive heart failure (CHF; New York Heart Association [NYHA] Classes II-IV) and history of myocardial infarction or unstable angina within 6 months before enrollment.
14.Unresolved toxicity grade > 2 from previous anti-tumor treatments

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: Evaluate the efficacy of trastuzumab in combination with pertuzumab and docetaxel in patients with HER2 mutated advanced NSCLC;Secondary Objective: - Confirmed Objective response rate (ORR) at 6 weeks<br>- Progression-Free Survival (PFS)<br>- Duration of response<br>- Overall survival<br>- Safety<br>;Primary end point(s): Overall response;Timepoint(s) of evaluation of this end point: This event could occur at any point during the study.